Statistics from Altmetric.com
Randomised controlled trial.
Forty one centres in the US; June 2004 to August 2005.
509 outpatients (18–65 years old) with DSM-IV bipolar I (n = 338) or II (n = 171) disorder experiencing a major depressive episode (17-item Hamilton Depression Rating Scale (HAM-D17) score ⩾20, HAM-D17 Item 1 score ⩾2; Young Mania Rating Scale score ⩽12). Participants were excluded if they had: been diagnosed with another Axis I disorder that had been treated within 6 months before the study; a current depressive episode lasting more than 12 months or less than 4 …
For correspondence: Michael H Thase, MD, Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, USA;
Source of funding: AstraZeneca Pharmaceuticals LP.
Competing interests: Dr Goodwin has been reimbursed by AstraZeneca for advice about the investigation of quetiapine for the presentation of the data presented in this paper at international meetings and CME activity on other topics. He has also advised the other companies with an interest in this field and presented at their educational meetings.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.